<div id="readability-page-1"><div><p>Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) has opened Q1 2026 with revenue of ¥433.1 million and basic EPS of ¥0.23, against a backdrop of trailing twelve month revenue of about ¥1.6 billion and basic EPS of ¥0.72 that has been associated with very large year over year earnings expansion and a higher net margin of 18.6% versus 7.6% a year earlier. Over recent periods, revenue has moved from ¥980.5 million on a trailing basis in Q4 2024 to ¥1.6 billion by Q1 2026, while quarterly EPS has ranged from ¥0.06 in early 2025 to ¥0.23 in the latest quarter. In this context, investors are likely to focus on how firmly these margins are holding up during the current results season.</p> <p>See our full analysis for Biocytogen Pharmaceuticals (Beijing).</p><p>With the latest numbers on the table, the next step is to see how this earnings profile lines up against the prevailing narratives around Biocytogen Pharmaceuticals (Beijing), and which views the new margin picture supports or challenges.</p> <p>Curious how numbers become stories that shape markets? Explore Community Narratives</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f8a66c7a-0be1-47d6-bc97-3d1e913867e8/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA0LTI4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f8a66c7a-0be1-47d6-bc97-3d1e913867e8/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA0LTI4"/><figcaption>SEHK:2315 Revenue &amp; Expenses Breakdown as at Apr 2026</figcaption></figure> <h2>TTM net income reaches ¥290.5 million</h2> <ul> <li>On a trailing twelve month basis, net income is ¥290.5 million on ¥1.6b of revenue, compared with ¥33.5 million of net income on ¥980.5 million of revenue a year earlier.</li> <li>What stands out for a bullish view is how this earnings ramp aligns with the idea of a “platform plus pipeline” story. However, the data also show that most of the progress is still coming from the existing business rather than any sudden single product shift:     <ul> <li>Trailing EPS moved from ¥0.08 to ¥0.72 over the same period, which is a very large increase and heavily supports bulls who focus on earnings momentum.</li> <li>At the same time, quarterly revenue in Q1 2026 of ¥433.1 million is relatively close to Q4 2025 at ¥437.9 million. Anyone taking the bullish view still has to keep in mind that the recent strength is spread across several quarters instead of being driven by a one off surge.</li> </ul> </li> </ul> <h2>18.6% margin versus 7.6% last year</h2> <ul> <li>The trailing net margin sits at 18.6%, up from 7.6% a year earlier, while quarterly net income excluding extra items has ranged from ¥24.0 million in Q1 2025 to ¥135.8 million in Q4 2024 and ¥104.0 million in Q1 2026.</li> <li>Bears often worry that a company focused on drug development will struggle to keep profitability steady. The current figures partly challenge that view but also give them something to point to:     <ul> <li>The move in trailing net income from ¥33.5 million to ¥290.5 million supports the argument that margins at 18.6% are currently healthier than before, which runs against a bearish claim that the business cannot reach solid profitability.</li> <li>However, quarterly swings in net income from ¥23.9995 million to ¥135.8 million and then ¥104.0 million mean critics can still argue that profit levels move around a fair bit, which fits a more cautious stance on how smooth future margins may be.</li> </ul> </li> </ul><p> Investors who want to see how these margin trends fit into the wider debate about the stock can go deeper into both the optimistic and cautious takes in one place: Curious how numbers become stories that shape markets? Explore Community Narratives. </p><h2>P/E of 69.3x with price above DCF fair value</h2> <ul> <li>The shares trade at HK$51.70 with a P/E of 69.3x versus an industry average of 39.7x and peer average of 37.6x, while the DCF fair value is HK$47.72.</li> <li>What critics highlight here is that a rich valuation sits on top of the strong recent growth, and the numbers give both bullish and bearish investors clear talking points:     <ul> <li>The very large year over year earnings expansion and trailing EPS of ¥0.72 give bulls a reason to say the current premium could be tied to the stronger profit base compared with a year ago.</li> <li>On the other hand, the share price sitting above the HK$47.72 DCF fair value and the P/E sitting well above industry and peer levels is exactly the kind of data bears use when they argue that the stock already prices in a lot of good news.</li> </ul> </li> </ul> <h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Biocytogen Pharmaceuticals (Beijing)'s growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.</p> <p>If this mix of strong recent earnings and a premium P/E leaves you torn, take a closer look at the full picture now and weigh up the 2 key rewards and 1 important warning sign.</p> <h2>See What Else Is Out There</h2> <p>Biocytogen Pharmaceuticals (Beijing) currently carries a P/E of 69.3x with the share price above the HK$47.72 DCF fair value and earnings that move around from quarter to quarter.</p> <p>If you are uneasy about paying a premium for this level of volatility, it makes sense to compare it with 301 resilient stocks with low risk scores that aim for steadier returns and fewer surprises.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Biocytogen Pharmaceuticals (Beijing) might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

688796

02315

<p>Biocytogen Pharmaceuticals (Beijing) reported Q1 2026 revenue of ¥433.1 million and basic EPS of ¥0.23, reflecting significant year-over-year earnings growth and a net margin increase to 18.6% from 7.6%. The trailing twelve-month net income reached ¥290.5 million, supporting a bullish outlook despite concerns over profitability stability. The stock trades at HK$51.70 with a P/E of 69.3x, above industry averages, raising questions about valuation. Investors are encouraged to consider long-term trends and the company's growth potential amidst current market narratives.</p>

Biocytogen Pharmaceuticals Beijing Q1 Margin Expansion Reinforces Bullish Earnings Narratives